Search Results - "ALEDORT, L. M"

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis by White, 2nd, G C, Rosendaal, F, Aledort, L M, Lusher, J M, Rothschild, C, Ingerslev, J

Get more information

Idiopathic thrombocytopenic purpura : A practice guideline developed by explicit methods for the American Society of Hematology by GEORGE, J. N, WOOLF, S. H, LICHTIN, A. E, MCMILLAN, R, OKERBLOOM, J. A, REGAN, D. H, WARRIER, I, RASKOB, G. E, WASSER, J. S, ALEDORT, L. M, BALLEM, P. J, BLANCHETTE, V. S, BUSSEL, J. B, CINES, D. B, KELTON, J. G

Get full text

The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline by Aledort, L. M.

“…The establishment of dedicated comprehensive treatment centres more than a half century ago transformed the management of haemophilia in the United States…”
Get full text

Is the incidence and prevalence of inhibitors greater with recombinant products? Yes by Aledort, L. M.

Get full text

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity by Aledort, L. M.

“…Thrombosis is a rare but well‐recognized potential complication of Factor VIII Inhibitor Bypass Activity (FEIBA) infusion. Recombinant factor VIIa (rFVIIa) is…”
Get full text

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors by Key, N S, Aledort, L M, Beardsley, D, Cooper, H A, Davignon, G, Ewenstein, B M, Gilchrist, G S, Gill, J C, Glader, B, Hoots, W K, Kisker, C T, Lusher, J M, Rosenfield, C G, Shapiro, A D, Smith, H, Taft, E

“…To assess the safety and efficacy of a fixed dose of recombinant activated factor VII (rFVIIa; NovoSeven) in the home setting for mild to moderately severe…”
Get more information

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues by ALEDORT, L. M.

“…Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high‐titre inhibitors. Factor VIII…”
Get full text

Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients by SCARADAVOU, A, WOO, B, WOLOSKI, B. M. R, CUNNINGHAM-RUNDLES, S, ETTINGER, L. J, ALEDORT, L. M, BUSSEL, J. B

“…We report the results of intravenous anti-D (WinRho, WinRho SD) therapy in 261 non-splenectomized patients treated at the New York Hospital-Cornell Medical…”
Get full text

Can B‐domain deletion alter the immunogenicity of recombinant factor VIII? A meta‐analysis of prospective clinical studies by ALEDORT, L. M., NAVICKIS, R. J., WILKES, M. M.

“…See also Iorio A, Marcucci M, Makris M. Concentrate‐related inhibitor risk: is a difference always real? This issue, pp 2176–9. Summary.  Background: As a…”
Get full text

The effect of a specialized case management programme on the cost of factor replacement use in patients with bleeding disorders by Aledort, L. M.

Get full text

A Prospective Study of Treatment of Acquired (Autoimmune) Factor VIII Inhibitors With High-Dose Intravenous Gammaglobulin by Schwartz, Richard S., Gabriel, Don A., Aledort, Louis M., Green, David, Kessler, Craig M.

“…A decrease in inhibitor titer has been reported in some patients with acquired factor VIII inhibitors treated with intravenous gammaglobulin (IGIV). We have…”
Get full text

Can we prevent inhibitors in mild and moderate factor VIII‐deficient patients? by ALEDORT, L. M.

Get full text

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment by ALEDORT, L. M.

“…At the present time, the most significant complication of hemophilia therapy is the development of neutralizing antibodies (inhibitors) to factor (F) VIII,…”
Get full text

Disseminated Intravascular Coagulation Complicating Epstein-Barr Virus Infection in a Cardiac Transplant Recipient: A Case Report by O'Connor, D.S, Elmariah, S, Aledort, L.M, Pinney, S.P

“…Abstract Viral infections are particularly common after cardiac transplantation. Herein we have presented a case of Epstein-Barr infection that presented as a…”
Get full text

Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) by GERNSHEIMER, T. B., GEORGE, J. N., ALEDORT, L. M., TARANTINO, M. D., SUNKARA, U., MATTHEW GUO, D., NICHOL, J. L.

“…Background: Romiplostim is a peptibody protein that raises platelet counts during long‐term treatment of patients with chronic immune thrombocytopenia (ITP)…”
Get full text

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate by Oldenburg, J., Jiménez-Yuste, V., Peiró-Jordán, R., Aledort, L. M., Santagostino, E.

“…Summary Most studies on immune tolerance induction (ITI) therapy in haemophilia A patients are focused on primary ITI in children. Here we report on the ITI…”
Get full text

Another role for the VW molecule by ALEDORT, L. M.

“…My comments on the implication of the vW molecule in down‐regulating the immunogenicity of factor VIII…”
Get full text

The EPIC study: a lesson to learn by Auerswald, G., Kurnik, K., Aledort, L. M., Chehadeh, H., Loew-Baselli, A., Steinitz, K., Reininger, A. J.

“…Introduction Inhibitory antibodies to factor VIII occur in about 30% of previously untreated patients (PUPs) and are the most serious complication of…”
Get full text

rFVIIa--its thrombogenicity by Aledort, L M

Get more information

Inhibitors occur more frequently in African–American and Latino Haemophiliacs by Aledort, L M, Dimichele, D M

Get full text